A Review on the Metabolism of 25 Peptide Drugs

Although peptide drugs make up only about 2% of all drugs approved by the United States Food and Drug Administration (FDA), they play important roles in the treatment of certain diseases where no small molecule drugs or therapeutic antibodies can fulfil. A primary reason for the strong preference of...

Full description

Saved in:
Bibliographic Details
Published in:International journal of peptide research and therapeutics 2021-06, Vol.27 (2), p.1397-1418
Main Author: Brian Chia, C. S.
Format: Article
Language:English
Subjects:
Animal Anatomy
Biochemistry
Biomedical and Life Sciences
Drug development
Drug metabolism
Drugs
FDA approval
Histology
Life Sciences
Metabolism
Molecular Medicine
Morphology
Peptides
Pharmaceutical Sciences/Technology
Pharmacology/Toxicology
Polymer Sciences
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although peptide drugs make up only about 2% of all drugs approved by the United States Food and Drug Administration (FDA), they play important roles in the treatment of certain diseases where no small molecule drugs or therapeutic antibodies can fulfil. A primary reason for the strong preference of small molecules over peptides is the latter’s susceptibility to degradation by human proteases, resulting in very short systemic half-lives. To circumvent this, peptide chemists have resorted to introducing unnatural amino acids and chemical modifications to enhance their metabolic stabilities. Hence, understanding how peptide drugs are metabolized by the human body will help in the design of more stable peptide drugs. This review covers 25 FDA-approved peptide drugs up to 20 residues in length and details their metabolic and degradation pathways in the human body after administration.
ISSN:1573-3149
1573-3904
DOI:10.1007/s10989-021-10177-0